Ventyx Biosciences Q2 EPS $(0.45) Beats $(0.57) Estimate
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences (NASDAQ:VTYX) reported a Q2 EPS of $(0.45), beating the analyst consensus estimate of $(0.57) by 21.05%. This represents a 50.55% improvement over the $(0.91) loss per share from the same period last year.
August 08, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ventyx Biosciences reported a Q2 EPS of $(0.45), beating estimates by 21.05% and showing a significant improvement from last year's $(0.91) per share loss.
Beating EPS estimates by a significant margin and showing substantial year-over-year improvement is likely to positively impact VTYX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100